To genetically convert ApoE4 into ApoE3 or ApoE2 proteins would be also hypothetically effective in reducing ApoE fragments since their structural properties make these proteins less susceptible to proteolytical cleavage; this would also protect against AD-related phenotypical alterations that have been extensively attributed to ApoE4 [17]. The gene discussed is APOE; the disease is Alzheimer disease.